Health-technology company Intrivo has launched its rapid Covid-19 test called On/Go One for the detection of all major known variants, including Omicron.
Recently, the company has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for the On/Go One rapid Covid-19 test.
Suitable for individuals with or without symptoms, the one easy-to-use test offers results with 98.2% accuracy in 15 minutes.
Intrivo co-CEO Ron Gutman said: “On/Go One represents the next frontier in Intrivo’s mission to help all Americans everywhere live happier, healthier, safer lives by helping to detect and control current and future variants and finally making the pandemic endemic once and for all.
“The team at Intrivo has brought all the experience we’ve accumulated over the past couple of years supplying millions and millions of tests to everyone from Government to schools, and from large enterprises to individual consumers, to create an all-in-one solution empowering everyone to go on the offense against Covid-19.”
Using On/Go companion mobile app, the users will be able to receive testing guidance, live non-medical support, instructional videos and virtual health resources to make the test easily.
Users will be directed to an Advanced Care Toolkit (ACT), which offers access to a team of Care Guides, in the event of a positive result.
For medical support, On/Go has collaborated with UnitedHealthcare’s Optum to facilitate immediate access to same-day virtual appointments with a trained medical provider.
The Intrivo population health management platform is said to support tests from multiple manufacturers, including On/Go One. It will enable population health managers plan, predict and prevent the next outbreak.
